vs
Side-by-side financial comparison of AvalonBay Communities (AVB) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $767.9M, roughly 1.4× AvalonBay Communities). AvalonBay Communities runs the higher net margin — 9040.6% vs 17.1%, a 9023.5% gap on every dollar of revenue. On growth, AvalonBay Communities posted the faster year-over-year revenue change (3.7% vs 2.5%). AvalonBay Communities produced more free cash flow last quarter ($1.4B vs $215.2M). Over the past eight quarters, AvalonBay Communities's revenue compounded faster (3.8% CAGR vs 1.5%).
AvalonBay Communities, Inc. is a publicly traded real estate investment trust that invests in apartments.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
AVB vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $767.9M | $1.0B |
| Net Profit | $166.0M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | 64.2% | 22.6% |
| Net Margin | 9040.6% | 17.1% |
| Revenue YoY | 3.7% | 2.5% |
| Net Profit YoY | -41.2% | -10.9% |
| EPS (diluted) | $1.18 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $767.9M | $1.0B | ||
| Q3 25 | $766.8M | $1.0B | ||
| Q2 25 | $760.2M | $1.0B | ||
| Q1 25 | $745.9M | $1.0B | ||
| Q4 24 | $740.5M | $1.0B | ||
| Q3 24 | $734.3M | $988.0M | ||
| Q2 24 | $726.0M | $1.0B | ||
| Q1 24 | $712.9M | $1.0B |
| Q4 25 | $166.0M | $179.1M | ||
| Q3 25 | $381.3M | $187.2M | ||
| Q2 25 | $268.7M | $194.9M | ||
| Q1 25 | $236.6M | $-17.4M | ||
| Q4 24 | $282.1M | $201.0M | ||
| Q3 24 | $372.5M | $178.6M | ||
| Q2 24 | $253.9M | $194.5M | ||
| Q1 24 | $173.4M | $169.9M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% | ||
| Q1 24 | — | 53.3% |
| Q4 25 | 64.2% | 22.6% | ||
| Q3 25 | 65.7% | 22.6% | ||
| Q2 25 | 67.6% | 24.9% | ||
| Q1 25 | 68.5% | -0.7% | ||
| Q4 24 | 63.1% | 22.5% | ||
| Q3 24 | 65.4% | 23.3% | ||
| Q2 24 | 66.6% | 24.1% | ||
| Q1 24 | 67.2% | 20.7% |
| Q4 25 | 9040.6% | 17.1% | ||
| Q3 25 | 49.7% | 17.8% | ||
| Q2 25 | 35.3% | 19.0% | ||
| Q1 25 | 31.7% | -1.7% | ||
| Q4 24 | 38.1% | 19.7% | ||
| Q3 24 | 50.7% | 18.1% | ||
| Q2 24 | 35.0% | 19.2% | ||
| Q1 24 | 24.3% | 16.7% |
| Q4 25 | $1.18 | $0.79 | ||
| Q3 25 | $2.68 | $0.84 | ||
| Q2 25 | $1.88 | $0.86 | ||
| Q1 25 | $1.66 | $-0.08 | ||
| Q4 24 | $1.99 | $0.87 | ||
| Q3 24 | $2.61 | $0.75 | ||
| Q2 24 | $1.78 | $0.82 | ||
| Q1 24 | $1.22 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $187.2M | $2.4B |
| Total DebtLower is stronger | $9.3B | $2.5B |
| Stockholders' EquityBook value | $11.6B | $5.2B |
| Total Assets | $22.2B | $9.2B |
| Debt / EquityLower = less leverage | 0.80× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $187.2M | $2.4B | ||
| Q3 25 | $123.3M | $2.2B | ||
| Q2 25 | $102.8M | $1.9B | ||
| Q1 25 | $53.3M | $1.6B | ||
| Q4 24 | $108.6M | $2.0B | ||
| Q3 24 | $552.4M | $2.3B | ||
| Q2 24 | $545.8M | $2.4B | ||
| Q1 24 | $287.9M | $2.2B |
| Q4 25 | $9.3B | $2.5B | ||
| Q3 25 | $8.7B | $2.5B | ||
| Q2 25 | $8.7B | $2.5B | ||
| Q1 25 | $8.3B | $2.5B | ||
| Q4 24 | $8.1B | $2.5B | ||
| Q3 24 | $8.4B | $2.5B | ||
| Q2 24 | $8.4B | $2.5B | ||
| Q1 24 | $8.0B | $2.6B |
| Q4 25 | $11.6B | $5.2B | ||
| Q3 25 | $11.9B | $5.0B | ||
| Q2 25 | $11.9B | $4.8B | ||
| Q1 25 | $11.9B | $4.6B | ||
| Q4 24 | $11.9B | $4.8B | ||
| Q3 24 | $11.9B | $5.1B | ||
| Q2 24 | $11.7B | $5.0B | ||
| Q1 24 | $11.7B | $4.8B |
| Q4 25 | $22.2B | $9.2B | ||
| Q3 25 | $21.9B | $9.0B | ||
| Q2 25 | $21.8B | $8.8B | ||
| Q1 25 | $21.2B | $8.5B | ||
| Q4 24 | $21.0B | $8.7B | ||
| Q3 24 | $21.3B | $9.2B | ||
| Q2 24 | $21.0B | $8.9B | ||
| Q1 24 | $20.6B | $8.7B |
| Q4 25 | 0.80× | 0.48× | ||
| Q3 25 | 0.73× | 0.50× | ||
| Q2 25 | 0.72× | 0.52× | ||
| Q1 25 | 0.70× | 0.55× | ||
| Q4 24 | 0.68× | 0.53× | ||
| Q3 24 | 0.70× | 0.49× | ||
| Q2 24 | 0.71× | 0.51× | ||
| Q1 24 | 0.68× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7B | $229.9M |
| Free Cash FlowOCF − Capex | $1.4B | $215.2M |
| FCF MarginFCF / Revenue | 183.5% | 20.5% |
| Capex IntensityCapex / Revenue | 34.1% | 1.4% |
| Cash ConversionOCF / Net Profit | 10.07× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $2.5B | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7B | $229.9M | ||
| Q3 25 | $477.0M | $355.1M | ||
| Q2 25 | $377.8M | $343.3M | ||
| Q1 25 | $415.9M | $169.4M | ||
| Q4 24 | $1.6B | $189.3M | ||
| Q3 24 | $486.2M | $367.0M | ||
| Q2 24 | $380.0M | $405.8M | ||
| Q1 24 | $412.9M | $292.4M |
| Q4 25 | $1.4B | $215.2M | ||
| Q3 25 | $402.2M | $341.4M | ||
| Q2 25 | $317.1M | $330.5M | ||
| Q1 25 | $367.5M | $153.9M | ||
| Q4 24 | $1.4B | $172.5M | ||
| Q3 24 | $434.2M | $350.6M | ||
| Q2 24 | $333.0M | $385.3M | ||
| Q1 24 | $375.4M | $279.6M |
| Q4 25 | 183.5% | 20.5% | ||
| Q3 25 | 52.5% | 32.5% | ||
| Q2 25 | 41.7% | 32.3% | ||
| Q1 25 | 49.3% | 15.3% | ||
| Q4 24 | 191.0% | 16.9% | ||
| Q3 24 | 59.1% | 35.5% | ||
| Q2 24 | 45.9% | 38.1% | ||
| Q1 24 | 52.7% | 27.5% |
| Q4 25 | 34.1% | 1.4% | ||
| Q3 25 | 9.8% | 1.3% | ||
| Q2 25 | 8.0% | 1.3% | ||
| Q1 25 | 6.5% | 1.5% | ||
| Q4 24 | 26.1% | 1.6% | ||
| Q3 24 | 7.1% | 1.7% | ||
| Q2 24 | 6.5% | 2.0% | ||
| Q1 24 | 5.3% | 1.3% |
| Q4 25 | 10.07× | 1.28× | ||
| Q3 25 | 1.25× | 1.90× | ||
| Q2 25 | 1.41× | 1.76× | ||
| Q1 25 | 1.76× | — | ||
| Q4 24 | 5.70× | 0.94× | ||
| Q3 24 | 1.31× | 2.05× | ||
| Q2 24 | 1.50× | 2.09× | ||
| Q1 24 | 2.38× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVB
Segment breakdown not available.
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
